Investment and Company Research
Opportunity Research
MICRO CAP HOT TOPICS
 

November 13, 2013

NEW AND LARGE MARKET OPPORTUNITY TO DRIVE LIFEAPPS VALUE

Yesterday, LifeApps Digital Media Inc. (OTCQB – LFAP - $0.073 – Spec Buy) issued a press release that should have a profound and major positive effect on business and the stock going forward and heading into 2014. As we have alluded to in recent articles, the company has operated in the health and fitness arena with solid success. With the passing of recent legislation, and the expectation that the mobile or mHealth space could reach $26 billion by 2017, LFAP has elected to turn to its strengths and focus on this fast-growing, critical services arena which leverages its existing strengths.

The "Telehealth Enhancement Act of 2013" (H.R. 3306) calls for Medicare home health payments to account for remote patient monitoring and expands coverage to all critical access and sole community hospitals, regardless of metropolitan status. The package also covers home-based video services for hospice care, home dialysis and homebound beneficiaries.

LifeApps has a history of working with medical professionals in creating healthy lifestyle mobile apps such as the highly rated MDWorkout® application. LifeApps is actively pursuing mHealth products and services for 2014 in conjunction with strategic partners in the fields of diabetes, smoking cessation and obesity related chronic disease. Products will expand on LifeApps' tutorial app platform with enhanced feature sets and advanced interactivity.

These diseases represent critical issues affecting large portions of the populations and LifeApps is well-positioned to serve as an adjunct provider of tools to reduce these chronic and widespread diseases. One in twelve Americans has been diagnosed with diabetes and another 79 million have pre-diabetes. According to www.Lung.org, cigarette smoking is the number one cause of preventable disease and death worldwide and results in $96 billion in direct health care expenditures in the U.S alone. With soaring medical costs related to obesity in the U.S. that exceed $110 billion, LifeApps will help provide solutions for advanced mHealth systems for continued patient care in these critical avenues. mHealth tools will improve positive patient outcomes and help to reduce health care costs overall.

With a rising stock price on increasing volume in the recent sideways to down market, LFAP looks like a great buy at current levels.

For more information, refer to our previous sponsored LFAP Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com

Senior Analyst: Robert Goldman
Rob Goldman has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

Analyst Certification
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

Disclaimer
This Opportunity Research Hot Topics article was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. While stocks in the Opportunity format may have a higher risk profile, they typically offer greater upside as well. Since May 2013, Goldman Small Cap Research has been compensated $500 per article by a third party and $4,000 for a research report service.

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

This article is the opinion of Goldman Small Cap Research and was written based upon publicly available information and our own due diligence.  The Company has not endorsed or compensated Goldman Small Cap Research for this article. All information contained in this report was provided by the Company or derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com